General Western Blot Reagents
Abcam Itraconazole, Cytochrome p450 inhibitor, 100MG
MW 705.64 g/mol, Purity >99%. Cytochrome p450 CYP3A4 inhibitor (IC₅₀ = 16-26 nM for midazolam hydroxylation). Higher affinity for fungal enzymes over mammalian cytochrome p450. Limited ability to cross the blood-brain barrier. Antifungal activity.
The product is subject to the following: Abcam Restricted Use Statement
Abcam Honokiol, anti-inflammatory and chemotherapeutic agent, 10MG
MW 266.34 g/mol, Purity >98%. Potent scavenger of reactive oxygen species with antiangiogenic, antitumor and anti-inflammatory properties. Mechanisms of action include inhibition of ras signalling and activation of the mitochondrial transistion pore via cyclophilin D induction. Inhibits NF-κB signaling, upstream of VEGF. Blood-brain barrier permeable.
The product is subject to the following: Abcam Restricted Use Statement
Abcam CAY10585, HIF-1alpha inhibitor, 25MG
MW 435.5 Da, Purity >97%. HIF-1α inhibitor (IC₅₀ values are 2.6 and 0.7 μM for Hep3B and AGS cell lines respectively). Suppresses transcription of HIF-1 target genes VEGF and erythropoietin at 10 μM. Attenuates hypoxia-induced ANP secretion. Blunts BMP9-induced osteogenic signaling in MSCs.
The product is subject to the following: Abcam Restricted Use Statement
Abcam BRL-50481, Selective PDE7 inhibitor, 50MG
MW 244.27 Da, Purity >98%. Selective, competitive PDE7 inhibitor (IC₅₀ values are 0.15 and 12.1 μm for PDE7A and PDE7B respectively). Active in vivo and in vitro. Potentiates the anti-inflammatory effect of PDE4 inhibitor rolipram (ab120031). Cell and blood-brain barrier permeable.
The product is subject to the following: Abcam Restricted Use Statement
Abcam Clindamycin, inhibits protein synthesis, 50MG
MW 425 Da, Purity >99%. Broad spectrum antimicrobial agent. Active against Gram-positive and Gram-negative bacteria and selected protozoa. Competitive inhibitor of peptide formation in large 50S ribosomal unit. Orally active in vivo.
The product is subject to the following: Abcam Restricted Use Statement
Abcam Troglitazone, PPAR-gamma receptor agonist, 10MG
MW 441.5 Da, Purity >97%. Potent, selective PPAR-γ receptor agonist (EC₅₀ = 780 nM). No activity at PPAR-α or PPAR-δ (up to 10 mM). Orally active. Antidiabetic and anticancer agent. Active in vivo and in vitro.
The product is subject to the following: Abcam Restricted Use Statement
Abcam Herpes Simplex Virus type 1, 200UL
Herpes Simplex Virus type 1 is a Human alphaherpesvirus 1 strain 17 protein, expressed in Native and with >80% purity.
Protein/ Peptide/ Enzyme Synonyms: UL10, gM, Envelope glycoprotein M
Conjugation: Unconjugated
The product is subject to the following: Abcam Restricted Use Statement
Abcam BML-210, HDAC inhibitor, 1MG
MW 339.4 Da, Purity >98%. Histone deacetylase (HDAC) inhibitor (IC₅₀ = 87 μM). Induces changes in gene expression profile. Antiproliferative activity in vitro.
The product is subject to the following: Abcam Restricted Use Statement
Abcam Tamo x ifen citrate, Estrogen receptor antagonist and partial agonist, 1G
MW 563.65 g/mol, Purity >99%. Competitive estrogen receptor antagonist and partial agonist. Inhibits estrogen dependent gene transcription and tumor growth. Additionally decreases cardiac infarction and inhibits Kir2.1, Kir2.2 and Kir2.3 potassium channels (IC₅₀ values are 0.93, 0.87 and 0.31 μM, respectively).
The product is subject to the following: Abcam Restricted Use Statement
Abcam Dienogest, Steroidal progesterone, 25MG
MW 311.4 Da, Purity >99%. Steroidal progesterone. Non-ethinylated progestin structurally related to testosterone. Anti-androgenic and antiproliferative effects in vitro.
The product is subject to the following: Abcam Restricted Use Statement
Abcam Melatonin, Endogenous hormone agonist at MT1 and MT2 receptors, 50MG
MW 232.28 Da, Purity >99%. Agonist at melatonin MT1 and MT2 receptors. Endogenous hormone important in the control of the circadian rhythm. Wide range of pathophysiological functions including antioxidative and immunomodulatory effects.
The product is subject to the following: Abcam Restricted Use Statement
Abcam Scriptaid, HDAC inhibitor, 25MG
MW 326.35 g/mol, Purity >98%. Novel HDAC inhibitor, able to cause >100-fold increase in histone deacetylation. Less toxic than trichostatin A (ab120850). Induces cell cycle arrest in vitro and in vivo. .
The product is subject to the following: Abcam Restricted Use Statement
Abcam AS601245, JNK inhibitor, 5MG
MW 372.4 Da, Purity >95%. Potent, selective, ATP competitive JNK inhibitor (IC₅₀ values are 150, 220 and 70 nM for hJNK1,2 and 3 respectively). Reduces cell adhesion and migration in cancer cells. Shows neuroprotective, anti-ischemic effects in vivo. Blood-brain barrier and cell-permeable.
The product is subject to the following: Abcam Restricted Use Statement
Abcam Concanamycin C, H+-ATPase inhibitor, 100UG
MW 823.1 Da, Purity >98%. Potent, selective vacuolar-type H+-ATPase inhibitor. Macrolide antibiotic agent. Concanamycin A (ab144227) analog. Shows antiproliferative and potent antifungal effects.
The product is subject to the following: Abcam Restricted Use Statement
Abcam Pro-myristic acid, Negative control for MiTMAB™ and OcTMAB™, 5MG
MW 299.5 Da. Negative control molecule for use with MiTMAB™ ab120466 and OcTMAB™ ab120467. Pro-myristic acid is an *in vitro* inhibitor of dynamin I and II, targeting the PH (lipid binding) domain (IC50 = 9.2 µM for inhibition of dynamin I GTPase). Although cell-permeable, it is rapidly broken down by cellular esterases to release intracellular myristic acid, which is not a dynamin inhibitor (IC50 = ≥300 μM for receptor-mediated endocytosis). It can therefore be used as a negative control in cell-based studies with MiTMAB™ and/or OcTMAB™.
The product is subject to the following: Abcam Restricted Use Statement